Gambaran Umum
Bio-Path Holdings, Inc., headquartered in the United States, operates within the biotechnology sector, focusing primarily on the development of RNAi (RNA interference) therapeutics that inhibit enzymes or proteins where there are clear paths to efficacy. As a clinical-stage company, their key efforts center on treatments for hematologic malignancies and solid tumors. Notably, Bio-Path is advancing a portfolio of nucleic acid cancer drugs with its proprietary DNAbilize® technology—a lipid nanoparticle delivery system. Major projects include preclinical and clinical trials targeting acute myeloid leukemia and chronic myeloid leukemia, among other cancers, deploying strategies that facilitate systemic administration with minimal toxicities, thereby aiming to improve patient outcomes in cancer care.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Bio-Path Holdings, Inc. per 2025 Jun 30 adalah -13.06 MM.
- Nilai net income untuk Bio-Path Holdings, Inc. per 2025 Jun 30 adalah -12.32 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -13.06 | -12.32 | |
2025-03-31 | -11.54 | -9.59 | |
2024-12-31 | -11.99 | -9.89 | |
2024-09-30 | -12.40 | -10.51 | |
2024-06-30 | -13.04 | -11.60 | |
2024-03-31 | -14.25 | -13.96 | |
2023-12-31 | -15.84 | -16.08 | |
2023-09-30 | -16.80 | -16.67 | |
2023-06-30 | -17.07 | -17.01 | |
2023-03-31 | -15.83 | -15.78 | |
2022-12-31 | -13.90 | -13.87 | |
2022-09-30 | -14.03 | -14.02 | |
2022-06-30 | -12.55 | -12.55 | |
2022-03-31 | -11.35 | -11.35 | |
2021-12-31 | -10.44 | -10.44 | |
2021-09-30 | -8.88 | -8.87 | |
2021-06-30 | -9.78 | -9.77 | |
2021-03-31 | -10.01 | -10.01 | |
2020-12-31 | -10.91 | -10.88 | |
2020-09-30 | -10.77 | -10.72 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -2.17.
- laba per saham yang terdilusi untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -2.17.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -2.17 | -2.17 |
2025-03-31 | -2.39 | -2.39 |
2024-12-31 | -4.12 | |
2024-09-30 | -7.13 | -7.12 |
2024-06-30 | -13.74 | -13.74 |
2024-03-31 | -25.84 | -25.84 |
2023-12-31 | -33.64 | |
2023-09-30 | -39.67 | -39.69 |
2023-06-30 | -44.29 | -44.30 |
2023-03-31 | -42.20 | -42.20 |
2022-12-31 | -38.10 | -38.12 |
2022-09-30 | -39.15 | -39.15 |
2022-06-30 | -35.19 | -35.21 |
2022-03-31 | -32.05 | -32.06 |
2021-12-31 | -31.05 | |
2021-09-30 | -29.52 | -29.52 |
2021-06-30 | -37.78 | -37.78 |
2021-03-31 | -45.95 | -45.95 |
2020-12-31 | -56.57 | |
2020-09-30 | -60.02 | -60.02 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Bio-Path Holdings, Inc. per 2025 Jun 30 adalah -7.91 MM.
- Nilai kas dari aktivitas pendanaan untuk Bio-Path Holdings, Inc. per 2025 Jun 30 adalah 3.90 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -7.91 | 3.90 | |
2025-03-31 | -10.85 | 10.78 | |
2024-12-31 | -10.57 | 10.70 | |
2024-09-30 | -9.51 | 7.72 | |
2024-06-30 | -8.86 | 9.42 | |
2024-03-31 | -8.92 | 2.38 | |
2023-12-31 | -11.54 | 2.20 | |
2023-09-30 | -14.72 | 0.00 | 3.42 |
2023-06-30 | -15.31 | 0.00 | 1.73 |
2023-03-31 | -16.23 | -0.02 | 1.73 |
2022-12-31 | -15.10 | -0.02 | 1.73 |
2022-09-30 | -12.90 | -0.04 | -0.00 |
2022-06-30 | -12.42 | -0.04 | 1.40 |
2022-03-31 | -10.87 | -0.07 | 1.40 |
2021-12-31 | -9.92 | -0.07 | 20.01 |
2021-09-30 | -9.71 | -0.05 | 24.30 |
2021-06-30 | -9.17 | -0.05 | 22.90 |
2021-03-31 | -10.00 | 22.90 | |
2020-12-31 | -10.96 | 4.29 | |
2020-09-30 | -10.61 | 7.29 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -0.18.
- p/libro untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -0.67.
- p/tbv untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -0.67.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -0.18 | -0.67 | -0.67 |
2025-03-31 | -0.09 | 5.87 | 5.87 |
2024-12-31 | -7.08 | -7.08 | |
2024-09-30 | -0.20 | 1.83 | 1.83 |
2024-06-30 | -0.26 | -1.36 | -1.36 |
2024-03-31 | -0.17 | 6.22 | 6.22 |
2023-12-31 | -0.35 | 2.33 | 2.33 |
2023-09-30 | -0.25 | 0.84 | 0.84 |
2023-06-30 | -0.89 | 1.54 | 1.54 |
2023-03-31 | -0.80 | 0.78 | |
2022-12-31 | 0.74 | 0.74 | |
2022-09-30 | 1.19 | 1.19 | |
2022-06-30 | -2.43 | 1.24 | 1.24 |
2022-03-31 | -2.62 | 1.07 | 1.07 |
2021-12-31 | -3.05 | 0.92 | 0.92 |
2021-09-30 | -3.67 | 1.20 | 1.20 |
2021-06-30 | |||
2021-03-31 | -2.01 | 0.64 | 0.64 |
2020-12-31 | -1.21 | 0.87 | 0.87 |
2020-09-30 | -1.00 | 0.81 | 0.81 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -5.91.
- EBIT (3 tahun) / EV untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -7.85.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -5.91 | -7.85 |
2025-03-31 | 36.84 | 49.20 |
2024-12-31 | -2.35 | -3.01 |
2024-09-30 | 7.08 | 8.60 |
2024-06-30 | -4.12 | -4.04 |
2024-03-31 | -9.51 | -7.96 |
2023-12-31 | -4.73 | -3.74 |
2023-09-30 | -21.36 | -16.47 |
2023-06-30 | -2.17 | -1.75 |
2023-03-31 | -20.40 | -17.27 |
2022-12-31 | 8.20 | 6.55 |
2022-09-30 | -2.03 | -1.74 |
2022-06-30 | -1.80 | -1.64 |
2022-03-31 | -2.92 | -2.87 |
2021-12-31 | -19.11 | -20.35 |
2021-09-30 | -1.26 | -1.23 |
2021-06-30 | ||
2021-03-31 | 0.94 | 0.89 |
2020-12-31 | 17.30 | 14.87 |
2020-09-30 | 7.72 | 6.65 |
Efektivitas Manajemen
- roa untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -1.87.
- roe untuk Bio-Path Holdings, Inc. pada 2025 Jun 30 adalah -7.43.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -1.87 | -7.43 | |||
2025-03-31 | -5.60 | -41.75 | 0.51 | -44.62 | |
2024-12-31 | -3.26 | -23.84 | |||
2024-09-30 | -2.31 | -4.59 | -8.60 | 0.42 | -6.57 |
2024-06-30 | -1.26 | -1.53 | |||
2024-03-31 | -1.01 | -1.13 | -29.02 | -16.84 | -20.82 |
2023-12-31 | -0.90 | -1.03 | -6.25 | -4.24 | -5.52 |
2023-09-30 | -0.81 | -0.87 | -3.26 | -2.61 | -2.94 |
2023-06-30 | -0.75 | -0.81 | -3.26 | -2.61 | -2.94 |
2023-03-31 | -0.58 | -0.62 | -1.70 | -1.56 | -1.74 |
2022-12-31 | -0.46 | -0.48 | -0.85 | -0.79 | -0.78 |
2022-09-30 | -0.41 | -0.43 | -0.85 | -0.79 | -0.78 |
2022-06-30 | -0.36 | -0.38 | -0.63 | -0.56 | -0.63 |
2022-03-31 | -0.32 | -0.33 | -0.50 | -0.42 | -0.48 |
2021-12-31 | -0.54 | -0.59 | -0.41 | 0.39 | -0.33 |
2021-09-30 | -0.60 | -0.74 | -0.30 | 0.49 | -0.31 |
2021-06-30 | -0.56 | -0.61 | -0.33 | 0.46 | -0.31 |
2021-03-31 | -0.50 | -0.56 | -0.32 | 0.41 | -0.32 |
2020-12-31 | -0.48 | -0.52 | -0.71 | -0.43 | -0.71 |
2020-09-30 | -0.61 | -0.67 | -0.79 | -0.25 | -0.78 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1133818 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |